Jan. 16 at 10:47 PM
$AUPH I believe it's been mentioned on here before but as annoyed and INPATIENT as I am this does provide hope. Got to wonder what the combined price of a successful BAFF/ April inhibitor plus an approved drug currently bringing in revenue is worth
Stage matters a lot
Phase II asset with strong mechanistic plausibility → can justify
$3.X–
$6 B+ deals (see Alpine).
Earlier assets (preclinical/Phase I) tend to be much lower — in the low hundreds of millions up to ~
$1.X B+ with milestone upside.
✅ Mechanistic breadth = valuation upside
Dual-pathway inhibitors (like BAFF + APRIL) — especially in autoimmune/kidney disease — are more valuable than single-target assets. That was a major factor in the Alpine pricing.
